Soleno Therapeutics Inc (SLNO)

$56.14

+0.28

(+0.5%)

Market is closed - opens 8 PM, 05 Nov 2024

Performance

  • $54.88
    $56.49
    $56.14
    downward going graph

    2.25%

    Downside

    Day's Volatility :2.86%

    Upside

    0.62%

    downward going graph
  • $21.30
    $57.28
    $56.14
    downward going graph

    62.06%

    Downside

    52 Weeks Volatility :62.81%

    Upside

    1.99%

    downward going graph

Returns

PeriodSoleno Therapeutics IncIndex (Russel 2000)
3 Months
23.34%
0.0%
6 Months
21.59%
0.0%
1 Year
141.71%
0.0%
3 Years
366.02%
-26.4%

Highlights

Market Capitalization
2.2B
Book Value
$7.31
Earnings Per Share (EPS)
-1.83
PEG Ratio
0.0
Wall Street Target Price
73.13
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-25.55%
Return On Equity TTM
-44.62%
Revenue TTM
0.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
0.0
EBITDA
-66.5M
Diluted Eps TTM
-1.83
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-2.42
EPS Estimate Next Year
-2.08
EPS Estimate Current Quarter
-0.6
EPS Estimate Next Quarter
-0.62

Analyst Recommendation

Buy
    91%Buy
    8%Hold
    0
    0%Sell
Based on 12 Wall street analysts offering stock ratings for Soleno Therapeutics Inc(by analysts ranked 0 to 5 stars)
Based on 12 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
11
11
10
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 30.26%

Current $56.14
Target $73.13

Technicals Summary

Sell

Neutral

Buy

Soleno Therapeutics Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Soleno Therapeutics Inc
Soleno Therapeutics Inc
12.55%
21.59%
141.71%
366.02%
140.26%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-16.71%
-12.0%
1.34%
30.26%
171.22%
Biontech Se
Biontech Se
-9.13%
19.42%
11.8%
-59.3%
487.66%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
2.21%
81.13%
63.87%
47.62%
198.57%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
3.47%
17.05%
22.13%
142.58%
136.25%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Soleno Therapeutics Inc
Soleno Therapeutics Inc
NA
NA
0.0
-2.42
-0.45
-0.26
NA
7.31
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
20.75
20.75
1.18
44.77
0.17
0.08
NA
242.47
Biontech Se
Biontech Se
160.8
NA
0.04
-2.76
-0.03
-0.02
NA
80.22
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
NA
NA
-0.49
-2.39
-15.01
0.02
NA
-0.02
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
32.84
NA
1.21
0.16
-0.03
0.13
NA
57.26
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Soleno Therapeutics Inc
Soleno Therapeutics Inc
Buy
$2.2B
140.26%
NA
0.0%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$101.7B
171.22%
20.75
32.04%
Biontech Se
Biontech Se
Buy
$27.1B
487.66%
160.8
-18.75%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
Buy
$36.5B
198.57%
NA
-3.11%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$122.9B
136.25%
32.84
-4.74%

Institutional Holdings

  • Vivo Capital, LLC

    18.82%
  • Nantahala Capital Management, LLC

    15.86%
  • The Carlyle Group Inc

    10.47%
  • HHG PLC

    8.64%
  • Perceptive Advisors LLC

    8.24%
  • Adage Capital Partners Gp LLC

    7.34%

Company Information

soleno therapeutics, inc. is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. the company is currently advancing its lead candidate, dccr, a once-daily oral tablet for the treatment of pws, into a phase iii clinical development program in early 2018.

Organization
Soleno Therapeutics Inc
Employees
33
CEO
Dr. Anish Bhatnagar M.D.
Industry
Health Technology

FAQs